Berger Disease, IgA Nephropathy
Conditions
Keywords
Berger Disease, Berger's Disease, IGA Glomerulonephritis, IGA Nephropathy, Iga Nephropathy 1, Immunoglobulin A Nephropathy Nephritis, IGA Type Nephropathy, IGA
Brief summary
A Phase 3 Study with Atacicept in Subjects With IgA Nephropathy (ORIGIN 3)
Detailed description
This is a multi-part study comprising of the original Phase 2b study and the addition of a separate pivotal Phase 3 study. After the completion of the primary results for the Ph 2b dose ranging study, the pivotal study will evaluate the efficacy and safety of atacicept compared to placebo in reducing proteinuria in subjects with IgAN and persistent proteinuria despite being on a maximally tolerated dose (MTD) of a RASi. Safety, eGFR, serum immunoglobulins and Gd-IgA1 will also be clinically assessed. The clinical study is comprised of a 104wk double-blind treatment period, followed by a 52wk open-label treatment period and a 26wk safety follow-up period. The UPCR primary endpoint will be assessed after the first 200 patients are randomized.
Interventions
BIOLOGICALAtacicept
Once weekly subcutaneous (SC) injections by prefilled syringe
OTHERPlacebo to match Atacicept
Once weekly subcutaneous (SC) injections by prefilled syringe
Sponsors
Vera Therapeutics, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: * Must have the ability to understand and sign a written informed consent form * Male or female of ≥18 years of age * Total urine protein excretion ≥1.0 g per 24-hour or urine protein to creatinine ratio (UPCR) ≥1.0 mg/mg based on a 24-hour urine sample during the Screening Period * Diagnosis of IgAN as demonstrated by renal biopsy conducted within 10 years * eGFR ≥ 30 mL/min/1.73 m2, as per the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. * On a stable prescribed regimen of RAASi for at least 12 weeks that is at the maximum labeled or tolerated dose at Screening * Systolic blood pressure ≤150 mmHg and diastolic blood pressure ≤90 mmHg Key
Exclusion criteria
* IgAN secondary to another condition (e.g., liver cirrhosis), or other causes of mesangial IgA deposition including IgA vasculitis (i.e., Henoch-Schonlein purpura), systemic lupus erythematosus (SLE), dermatitis herpetiformis, ankylosing spondylitis * Total urine protein excretion ≥ 5g per 24-hour or urine protein to creatinine ratio (UPCR) ≥ 5 mg/mg based on a 24-hour urine sample during the Screening Period * Evidence of rapidly progressive glomerulonephritis (loss of ≥ 50% of eGFR within 3 months of screening) * Evidence of nephrotic syndrome within 6 months of screening (serum albumin \<30g/L in association with UPCR \>3.5 mg/mg * Renal or other organ transplantation prior to, or expected during the study * Concomitant chronic renal disease in addition to IgAN * Uncontrolled diabetes, defined as hemoglobin-A1c (HbA1c) \>7.5% at screening * History of tuberculosis (TB), untreated latent TB infection (LTBI), or evidence of active TB determined by a positive Quantiferon test * Participation in the Phase 2b (Parts A and B) study or any previous treatment with atacicept
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline in urine protein to creatinine ratio (UPCR) | 36 Weeks | UPCR based on 24 hour urine collection |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Annualized rate of change in estimated glomerular filtration rate (eGFR) | 52 and 104 Weeks | eGFR calculated by CKD-EPI formula |
Countries
United States
Outcome results
None listed